CDTX
Cidara TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
CDTX Profile
Cidara Therapeutics, Inc.
A biotech company that develops long-acting therapeutics
6310 Nancy Ridge Drive, Suite 101, San Diego, California 92121
--
Cidara Therapeutics, Inc., originally incorporated in Delaware in December 2012 under the name K2 Therapeutics, Inc., changed its name to Cidara Therapeutics, Inc., in July 2014. The Company is a biotechnology company focused on the discovery, development and commercialization of new anti-infectives for the treatment of diseases that are fully addressed by current standards of care therapies. CD101 is an echinocandin, a class of mature antifungal agents. The company's initial proprietary product candidate is its new compound, CD101, a therapeutic formulation for severe fungal infections. The company's first product is Alternate CD101 Intravenous, formerly biafungin, a potential once-a-week intravenous, or IV, treatment is being used for the development of treatment and prevention of systemic fungal infections. The company's second product candidate, CD101 for topical use, formerly known as topifungin, is an topical preparation CD101 for the treatment of vulvovaginal candidiasis, or VVC, a common mucosal infection. CD101 topical is the first topical application of echinocandin antifungal agents. In addition, the company has developed a proprietary immunotherapy technology platform, CloudbreakTM, which it uses to create compounds designed to guide a patient's immune cells to attack and destroy infectious diseases caused by pathogens. The company is developing its first cloud-breaking development candidate, C001, for the treatment of invasive aspergillosis, which causes fungal pathogens, Aspergillus infections. The company is evaluating more opportunities to expand its cloud-breaking immune platform, infectious diseases and other areas.
